INTRODUCTION: It has been demonstrated that urinary neutrophil gelatinase-associated lipocalin (NGAL) and calprotectin are helpful biomarkers in the differentiation of intrinsic and prerenal acute kidney injury. OBJECTIVE: The present cross-sectional study investigates, whether urinary biomarkers are able to differentiate primarily inflammatory from non-inflammatory entities in chronic kidney disease (CKD). METHODS: Urinary calprotectin, NGAL, and kidney injury molecule-1 (KIM-1) concentrations were assessed in a study population of 143 patients with stable CKD and 29 healthy controls. Stable renal function was defined as an eGFR fluctuation ≤5 ml/min/1.73 m2 in the past 12 months. Pyuria, metastatic carcinoma, and renal transplantation were regarded as exclusion criteria. Diabetic nephropathy, hypertensive nephropathy, and polycystic kidney disease were categorized as 'primarily non-inflammatory renal diseases' (NIRD), whereas glomerulonephritis and vasculitis were regarded as 'primarily inflammatory renal diseases' (IRD). RESULTS: Urinary calprotectin and NGAL concentrations significantly differed between CKD and healthy controls (p < 0.05 each), whereas KIM-1 concentrations did not (p = 0.84). The three biomarkers did neither show significant differences in-between the individual entities, nor the two categories of IRD vs. NIRD (calprotectin 155.7 vs. 96.99 ng/ml; NGAL 14 896 vs. 11 977 pg/ml; KIM-1 1388 vs. 1009 pg/ml; p > 0.05 each). Albumin exceeds the diagnostic power of the investigated biomarkers by far. CONCLUSIONS: The urinary biomarkers calprotectin, NGAL, and KIM-1 have no diagnostic value in the differentiation of primarily inflammatory vs. non-inflammatory etiologies of CKD.
INTRODUCTION: It has been demonstrated that urinary neutrophil gelatinase-associated lipocalin (NGAL) and calprotectin are helpful biomarkers in the differentiation of intrinsic and prerenal acute kidney injury. OBJECTIVE: The present cross-sectional study investigates, whether urinary biomarkers are able to differentiate primarily inflammatory from non-inflammatory entities in chronic kidney disease (CKD). METHODS: Urinary calprotectin, NGAL, and kidney injury molecule-1 (KIM-1) concentrations were assessed in a study population of 143 patients with stable CKD and 29 healthy controls. Stable renal function was defined as an eGFR fluctuation ≤5 ml/min/1.73 m2 in the past 12 months. Pyuria, metastatic carcinoma, and renal transplantation were regarded as exclusion criteria. Diabetic nephropathy, hypertensive nephropathy, and polycystic kidney disease were categorized as 'primarily non-inflammatory renal diseases' (NIRD), whereas glomerulonephritis and vasculitis were regarded as 'primarily inflammatory renal diseases' (IRD). RESULTS: Urinary calprotectin and NGAL concentrations significantly differed between CKD and healthy controls (p < 0.05 each), whereas KIM-1 concentrations did not (p = 0.84). The three biomarkers did neither show significant differences in-between the individual entities, nor the two categories of IRD vs. NIRD (calprotectin 155.7 vs. 96.99 ng/ml; NGAL 14 896 vs. 11 977 pg/ml; KIM-1 1388 vs. 1009 pg/ml; p > 0.05 each). Albumin exceeds the diagnostic power of the investigated biomarkers by far. CONCLUSIONS: The urinary biomarkers calprotectin, NGAL, and KIM-1 have no diagnostic value in the differentiation of primarily inflammatory vs. non-inflammatory etiologies of CKD.
Authors: Frank Heller; Sandra Frischmann; Maria Grünbaum; Walter Zidek; Timm H Westhoff Journal: Clin J Am Soc Nephrol Date: 2011-09-01 Impact factor: 8.237
Authors: Felix S Seibert; Christian Rosenberger; Susanne Mathia; Robert Arndt; Wolfgang Arns; Huppertz Andrea; Nikolaos Pagonas; Frederic Bauer; Walter Zidek; Timm H Westhoff Journal: Transplantation Date: 2017-02 Impact factor: 4.939
Authors: Thomas L Nickolas; Kai M Schmidt-Ott; Pietro Canetta; Catherine Forster; Eugenia Singer; Meghan Sise; Antje Elger; Omar Maarouf; David Antonio Sola-Del Valle; Matthew O'Rourke; Evan Sherman; Peter Lee; Abdallah Geara; Philip Imus; Achuta Guddati; Allison Polland; Wasiq Rahman; Saban Elitok; Nasir Malik; James Giglio; Suzanne El-Sayegh; Prasad Devarajan; Sudarshan Hebbar; Subodh J Saggi; Barry Hahn; Ralph Kettritz; Friedrich C Luft; Jonathan Barasch Journal: J Am Coll Cardiol Date: 2012-01-17 Impact factor: 24.094
Authors: Thomas L Nickolas; Matthew J O'Rourke; Jun Yang; Meghan E Sise; Pietro A Canetta; Nicholas Barasch; Charles Buchen; Faris Khan; Kiyoshi Mori; James Giglio; Prasad Devarajan; Jonathan Barasch Journal: Ann Intern Med Date: 2008-06-03 Impact factor: 25.391
Authors: Mark C Dessing; Alessandra Tammaro; Wilco P Pulskens; Gwendoline J Teske; Loes M Butter; Nike Claessen; Marco van Eijk; Tom van der Poll; Thomas Vogl; Johannes Roth; Sandrine Florquin; Jaklien C Leemans Journal: Kidney Int Date: 2014-06-18 Impact factor: 10.612